ReShape Lifesciences announces reverse merger with Vyome Therapeutics and asset sale for $5.16M

Vyome Holdings, Inc

Vyome stockholders will own 88.9% of combined company; ReShape stockholders to own 11.1%.
ReShape sells substantially all assets to Ninjour (Biorad Medisys affiliate) for $5.16M cash; Merger closes immediately after.
Series C Preferred liquidation preference reduced from $26.2M to at most $1M or 20% of asset sale price or excess net cash.
Up to $7.3M in concurrent financing includes $5.8M common stock at 30% discount to post-merger valuation.
CEO Paul Hickey receives severance increase to 18 months base salary and 4% fully diluted shares.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.